ORIC Pharmaceuticals, Inc.’s ORIC share price has dipped by 7.54%, which has investors questioning if this is right time to ...

On Tuesday, H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock.

ORIC Pharmaceuticals, Inc.’s ORIC share price has surged by 7.27%, which has investors questioning if this is right time to ...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best ...

In this article, we are going to take a look at where ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators ...

The last time I wrote an article on ORIC Pharmaceuticals (NASDAQ:ORIC) it was with respect to a Seeking Alpha article entitled "ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could ...

$ORIC insiders have traded $ORIC stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales. Here’s a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical ...

Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial ...